Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques

References

• Zerboni L, Sen N, Oliver SL, et al. Molecular mechanisms of Varicella Zoster Virus pathogenesis. Nat Rev Microbiol. 2014 Mar;12(3):197–210. doi:10.1038/nrmicro3215
   PubMed Web of Science ®Google Scholar
• Nordén R, Nilsson J, Samuelsson E, et al. Recombinant glycoprotein E of Varicella Zoster Virus contains glycan-peptide motifs that modulate B cell epitopes into discrete immunological signatures. Int J Mol Sci. 2019;20(4). doi:10.3390/ijms20040954
   PubMed Web of Science ®Google Scholar
• Chen T, Sun J, Zhang S, et al. Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design. Sci China Life Sci. 2023 Apr;66(4):743–753. doi:10.1007/s11427-022-2264-1
   PubMed Web of Science ®Google Scholar
• Lee SJ, Park HJ, Ko HL, et al. Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant. Immun Inflamm Dis. 2020;8(2):216–227. doi:10.1002/iid3.297
   PubMed Web of Science ®Google Scholar
• Wang L, Zhu L, Zhu H. Efficacy of varicella (VZV) vaccination: an update for the clinician. Ther Adv Vaccines. 2016;4(1-2):20–31. doi:10.1177/2051013616655980
   PubMedGoogle Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096. doi:10.1056/NEJMoa1501184
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–1032. doi:10.1056/NEJMoa1603800
   PubMed Web of Science ®Google Scholar
• Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81(10):928–930. doi:10.1212/WNL.0b013e3182a3516e
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008 Jun 6;57(Rr-5):1–30. quiz CE2-4.
   PubMedGoogle Scholar
• Asada H. VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study. Vaccine. 2019;37(44):6776–6781. doi:10.1016/j.vaccine.2019.09.031
   PubMed Web of Science ®Google Scholar
• Steain M, Sutherland JP, Rodriguez M, et al. Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia. J Virol. 2014;88(5):2704–2716. doi:10.1128/JVI.03445-13
   PubMed Web of Science ®Google Scholar
• Weinberg A, Levin MJ. VZV t cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341–357.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200(7):1068–1077. doi:10.1086/605611
   PubMed Web of Science ®Google Scholar
• Haberthur K, Engelmann F, Park B, et al. CD4 t cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. PLoS Pathog 2011;7(11):e1002367. doi:10.1371/journal.ppat.1002367
   PubMed Web of Science ®Google Scholar
• Traina-Dorge V, Palmer BE, Coleman C, et al. Reactivation of simian varicella virus in rhesus macaques after CD4 T cell depletion. J Virol. 2019;93(3. doi:10.1128/JVI.01375-18
   PubMed Web of Science ®Google Scholar
• Park HB, Kim KC, Park JH, et al. Association of reduced CD4 T cell responses specific to Varicella Zoster Virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. J Rheumatol. 2004 Nov;31(11):2151–2155.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279. doi:10.1038/nrd.2017.243
   PubMed Web of Science ®Google Scholar
• Verbeke R, Hogan MJ, Loré K, et al. Innate immune mechanisms of mRNA vaccines. Immunity. 2022;55(11):1993–2005. doi:10.1016/j.immuni.2022.10.014
   PubMed Web of Science ®Google Scholar
• Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–780. doi:10.1038/nrd4278
   PubMed Web of Science ®Google Scholar
• Li C, Lee A, Grigoryan L, et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat Immunol. 2022;23(4):543–555. doi:10.1038/s41590-022-01163-9
   PubMed Web of Science ®Google Scholar
• Monslow MA, Elbashir S, Sullivan NL, et al. Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates. Vaccine. 2020;38(36):5793–5802. doi:10.1016/j.vaccine.2020.06.062
   PubMed Web of Science ®Google Scholar
• Zhao H, Shao X, Yu Y, et al. A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. bioRxiv. 2023:2022.11.18.517095.
   Google Scholar
• Yang R, Deng Y, Huang B, et al. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct Target Ther. 2021;6(1):213. doi:10.1038/s41392-021-00634-z
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang L, Lin A, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. 2023;621(7978):396–403. doi:10.1038/s41586-023-06127-z
   PubMed Web of Science ®Google Scholar
• Lin A, Liang F, Thompson EA, et al. Rhesus macaque myeloid-derived suppressor cells demonstrate T cell inhibitory functions and are transiently increased after vaccination. J Immunol. 2018;200(1):286–294. doi:10.4049/jimmunol.1701005
   PubMed Web of Science ®Google Scholar
• Malavige GN, Jones L, Black AP, et al. Varicella Zoster Virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol. 2008;152(3):522–531. doi:10.1111/j.1365-2249.2008.03633.x
   PubMed Web of Science ®Google Scholar
• Lu LL, Suscovich TJ, Fortune SM, et al. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46–61. doi:10.1038/nri.2017.106
   PubMed Web of Science ®Google Scholar
• Boeren M, Meysman P, Laukens K, et al. T cell immunity in HSV-1- and VZV-infected neural ganglia. Trends Microbiol 2023;31(1):51–61. doi:10.1016/j.tim.2022.07.008
   PubMed Web of Science ®Google Scholar
• Alameh MG, Tombácz I, Bettini E, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54(12):2877–2892.e7. doi:10.1016/j.immuni.2021.11.001
   PubMed Web of Science ®Google Scholar
• Connors J, Joyner D, Mege NJ, et al. Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals. Commun Biol. 2023;6(1):188. doi:10.1038/s42003-023-04555-1
   PubMed Web of Science ®Google Scholar
• Lenart K, Hellgren F, Ols S, et al. A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. Mol Ther Methods Clin Dev. 2022;27:309–323. doi:10.1016/j.omtm.2022.10.001
   PubMed Web of Science ®Google Scholar
• Hellgren F, Cagigi A, Arcoverde Cerveira R, et al. Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses. Nat Commun. 2023;14(1):3713. doi:10.1038/s41467-023-39421-5
   PubMed Web of Science ®Google Scholar
• Thompson EA, Ols S, Miura K, et al. TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. JCI Insight. 2018;3(10). doi:10.1172/jci.insight.120692
   Web of Science ®Google Scholar
• Jonsson-Schmunk K, Ghose R, Croyle MA. Immunization and drug metabolizing enzymes: focus on hepatic cytochrome P450 3A. Expert Rev Vaccines. 2021;20(5):623–634. doi:10.1080/14760584.2021.1899818
   PubMed Web of Science ®Google Scholar
• McColl ER, Croyle MA, Zamboni WC, et al. COVID-19 Vaccines and the virus: impact on drug metabolism and pharmacokinetics. Drug Metab Dispos. 2023;51(1):130–141. doi:10.1124/dmd.122.000934
   PubMed Web of Science ®Google Scholar
• Fiore J, Co-van der Mee MM, Maldonado A, et al. Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance. Ther Adv Vaccines Immunother. 2021;9:25151355211057479.
   Google Scholar
• Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine. 2009;27(12):1787–1796. doi:10.1016/j.vaccine.2009.01.091
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol. 2018;39:14–21. doi:10.1016/j.smim.2018.05.001
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817–838. doi:10.1038/s41573-021-00283-5
   PubMed Web of Science ®Google Scholar
• Bogger-Goren S, Baba K, Hurley P, et al. Antibody response to varicella-zoster virus after natural or vaccine-induced infection. J Infect Dis. 1982;146(2):260–265. doi:10.1093/infdis/146.2.260
   PubMed Web of Science ®Google Scholar
• Levin MJ, Weinberg A. Immune responses to zoster vaccines. Hum Vaccin Immunother. 2019;15(4):772–777. doi:10.1080/21645515.2018.1560918
   PubMed Web of Science ®Google Scholar
• Tang H, Moriishi E, Okamoto S, et al. A community-based survey of varicella-zoster virus-specific immune responses in the elderly. J Clin Virol. 2012;55(1):46–50. doi:10.1016/j.jcv.2012.06.008
   PubMed Web of Science ®Google Scholar
• Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347(1):26–34. doi:10.1056/NEJMoa013441
   PubMed Web of Science ®Google Scholar
• Jennewein MF, Alter G. The immunoregulatory roles of antibody glycosylation. Trends Immunol 2017;38(5):358–372. doi:10.1016/j.it.2017.02.004
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8(3):226–234. doi:10.1038/nrd2804
   PubMed Web of Science ®Google Scholar
• Kao D, Lux A, Schaffert A, et al. Igg subclass and vaccination stimulus determine changes in antigen specific antibody glycosylation in mice. Eur J Immunol. 2017;47(12):2070–2079. doi:10.1002/eji.201747208
   PubMed Web of Science ®Google Scholar
• Mahan AE, Jennewein MF, Suscovich T, et al. Antigen-specific antibody glycosylation is regulated via vaccination. PLoS Pathog 2016;12(3):e1005456. doi:10.1371/journal.ppat.1005456
   PubMed Web of Science ®Google Scholar
• Sei JJ, Cox KS, Dubey SA, et al. Effector and central memory poly-functional CD4(+) and CD8(+) T cells are boosted upon ZOSTAVAX(®) vaccination. Front Immunol. 2015;6:553.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571. doi:10.1038/s41586-020-2622-0
   PubMed Web of Science ®Google Scholar
• Vogel AB, Kanevsky I, Che Y, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–289. doi:10.1038/s41586-021-03275-y
   PubMed Web of Science ®Google Scholar
• Chivukula S, Plitnik T, Tibbitts T, et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. NPJ Vaccines. 2021;6(1):153. doi:10.1038/s41541-021-00420-6
   PubMed Web of Science ®Google Scholar
• Coccia M, Collignon C, Hervé C, et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. NPJ Vaccines. 2017;2:25. doi:10.1038/s41541-017-0027-3
   PubMed Web of Science ®Google Scholar
• De Giovanni M, Cutillo V, Giladi A, et al. Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4(+) T cells. Nat Immunol. 2020;21(3):321–330. doi:10.1038/s41590-020-0596-6
   PubMed Web of Science ®Google Scholar
• Liang F, Lindgren G, Lin A, et al. Efficient targeting and activation of antigen-presenting cells In vivo after modified mRNA vaccine administration in rhesus macaques. Mol Ther. 2017;25(12):2635–2647. doi:10.1016/j.ymthe.2017.08.006
   PubMed Web of Science ®Google Scholar
• Nam HJ, Hong SJ, Lee A, et al. An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21. NPJ Vaccines. 2022;7(1):45. doi:10.1038/s41541-022-00467-z
   PubMed Web of Science ®Google Scholar
• Haberthur K, Messaoudi I. Animal models of Varicella Zoster Virus infection. Pathogens. 2013;2(2):364–382. doi:10.3390/pathogens2020364
   PubMedGoogle Scholar